Table 2.
Patients’ Characteristics (Age, Sex, Status, Child-Pugh Score, Stage, Etiology)
| Study | Abdel-Rahman et al.13 | Qin et al15 | Gish et al14 | Yeo et al16 | Abou Alfa et al.17 | Mok et al18 | |||
|---|---|---|---|---|---|---|---|---|---|
| Nolatrexed | Doxorubicin | Doxorubicin | PIAF | Doxorubicin+ Sorafenib | Doxorubicin | ||||
| Age | 53.5 (median) | 18–75 | NS | 15–75 | 38–82 (median 65y) | >18y | |||
| Sex | Mainly males | 88.7%males | NS | 91% males | 76% males | 90.7% males | |||
| Baseline status | ECOG PST 0–2 | KPS ≥70 | KPS ≥ 60 | ECOG PST 0–2 | ECOG PST 0–2 | KPS ≥ 70 | |||
| Child-Pugh | A-B | A(87.9%)-B(12.1%) | A 74.8% B 24.3% |
A 73.1% B 26.9% |
A 87.2% B 12.8% |
A 83% B 17% |
A | NS | |
| Stage | BCLC C | BCLC B(20%) or C(80%) | Using CLIP score 35.1% score 2 29.3% score 3 27.9% score 1 |
35.9% score 2 28.7% score 2 27.4% score 2 |
Okuda staging I 9% II 87% II 4% |
I 9% II 87% III 4% |
NS | NS | |
| Possible etiology | HCV 96% HBV 2% NASH 2% |
HBV 91.4% HCV 6.7% |
HCV 35.6% HBV26.1% History of Alcoholism29.3% |
HCV 43% HBV18.4% History of Alcoholism 26% |
HBV 85% HCV 9% |
HBV 87% HCV 4% |
HBV 6.4% HCV 21.3% |
HBV 14.3% HCV 14.3% |
HBV 78% |
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; KPS, Karnofesky performance status; NASH, non-alcoholic steatohepatitis; PIAF, cisplatin/interferon α−2b/doxorubicin/fluorouracil; PST, performance status.